GlassScriptPhysician profile
Thomas Oliver Stodgel
NPI 1609819630
$2,178.96
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $886 · 2020: $104 · 2021: $595 · 2022: $428 · 2023: $131 · 2024: $34.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $165.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $650.49 | 2019-2022 | |
| Therapeuticsmd, INC. | $167.40 | 2019-2022 | |
| Ethicon US, LLC | $165.68 | 2023-2024 | Harmonic, Dermabond, Stratafix |
| Merck Sharp & Dohme LLC | $136.96 | 2019 | |
| Mayne Pharma Commercial LLC | $121.00 | 2021-2022 | |
| Myovant Sciences INC. | $119.80 | 2021-2022 | |
| Roche Diagnostics Corporation | $90.86 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $68.75 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.34 | 2019-2022 | |
| Amag Pharmaceuticals, INC. | $51.18 | 2019 | |
| Avion Pharmaceuticals | $50.95 | 2019 | |
| Vertical Pharmaceuticals, LLC | $50.75 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $44.13 | 2022 | |
| Mylan Pharmaceuticals INC. | $36.55 | 2021 | |
| Pfizer INC. | $35.58 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lupin INC. | $32.33 | 2020 | |
| Coopersurgical, INC. | $32.05 | 2019-2021 | |
| Agile Therapeutics, INC. | $29.52 | 2021 | |
| Exeltis, USA INC. | $28.10 | 2019-2021 | |
| Sage Therapeutics, LLC | $27.96 | 2021 | |
| Lilly USA, LLC | $26.17 | 2019 | |
| Hologic Sales and Service, LLC | $23.99 | 2022 | |
| Aspira Women'S Health INC | $23.11 | 2022 | |
| Genentech USA, INC. | $21.61 | 2019 | |
| Astellas Pharma US INC | $18.61 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.37 | 2019 | |
| Organon LLC | $17.87 | 2021 | |
| Dysis Medical, INC. | $16.49 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $15.36 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Stodgel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.